Dong Liu1, Junxiao Wang2,3, Zhenhu Ma2, Ning Zhang4, Yun Zhao2, Xiang Yang2, Zhenyu Wen2,3, Hui Xie5. 1. Department of Radiology, The First Hospital of Tsinghua University, Beijing, 100016, China. 2. Department of Interventional Therapy, Fifth Medical Center of Chinese, PLA General Hospital, Beijing, 100039, China. 3. Department of Occupational and Environmental Health, School of Public Health, Jilin University, Changchun, Jilin, 130000, China. 4. Department of Liver Disease, Fifth Medical Center of Chinese, PLA General Hospital, Beijing, 100039, China. 5. Department of Interventional Therapy, Fifth Medical Center of Chinese, PLA General Hospital, Beijing, 100039, China. xh302jr@126.com.
Abstract
PURPOSE: This retrospective study evaluated the efficacy, safety, and factors affecting the prognosis of transarterial chemoembolisation with irinotecan-eluting beads with CalliSpheres (DEB-TACE) for intrahepatic cholangiocarcinoma (ICC). MATERIALS AND METHODS: We retrospectively collected data on 39 patients with unresectable ICC who received DEB-TACE therapy. We assessed the indicators of tumour response, progression-free survival (PFS), overall survival (OS), and the incidence of adverse events. PFS and OS were analysed using Kaplan-Meier curves, while Cox analysis was used to identify factors affecting the prognosis. RESULTS: The 3-month objective response rate (ORR) and disease control rate (DCR) of the 39 patients with unresectable ICC were 35.9% and 56.4%, respectively, while the 6-month ORR and DCR were 23.0% and 40.9%, respectively. The median OS and PFS were 11.0 months and 8.0 months, respectively. Cox analysis demonstrated that combined therapy (adjuvant sorafenib after DEB-TACE) and a low cancer antigen (CA) 125 level (≤ 35 U/ml) were independent favourable prognostic factors. Transient elevation of the aminotransferase level, nausea, vomiting, abdominal pain, fever, and hyper-bilirubinaemia were common adverse events in patients with unresectable ICC treated with DEB-TACE with CalliSphere beads (CBs). Hepatic abscess was the most serious complication, observed in one patient. CONCLUSIONS: DEB-TACE with CBs is a safe and well-tolerated therapy in patients with unresectable ICC with a low incidence of adverse events and relatively prolonged survival. Combined therapy and low CA125 are prognostic factors associated with longer survival.
PURPOSE: This retrospective study evaluated the efficacy, safety, and factors affecting the prognosis of transarterial chemoembolisation with irinotecan-eluting beads with CalliSpheres (DEB-TACE) for intrahepatic cholangiocarcinoma (ICC). MATERIALS AND METHODS: We retrospectively collected data on 39 patients with unresectable ICC who received DEB-TACE therapy. We assessed the indicators of tumour response, progression-free survival (PFS), overall survival (OS), and the incidence of adverse events. PFS and OS were analysed using Kaplan-Meier curves, while Cox analysis was used to identify factors affecting the prognosis. RESULTS: The 3-month objective response rate (ORR) and disease control rate (DCR) of the 39 patients with unresectable ICC were 35.9% and 56.4%, respectively, while the 6-month ORR and DCR were 23.0% and 40.9%, respectively. The median OS and PFS were 11.0 months and 8.0 months, respectively. Cox analysis demonstrated that combined therapy (adjuvant sorafenib after DEB-TACE) and a low cancer antigen (CA) 125 level (≤ 35 U/ml) were independent favourable prognostic factors. Transient elevation of the aminotransferase level, nausea, vomiting, abdominal pain, fever, and hyper-bilirubinaemia were common adverse events in patients with unresectable ICC treated with DEB-TACE with CalliSphere beads (CBs). Hepatic abscess was the most serious complication, observed in one patient. CONCLUSIONS: DEB-TACE with CBs is a safe and well-tolerated therapy in patients with unresectable ICC with a low incidence of adverse events and relatively prolonged survival. Combined therapy and low CA125 are prognostic factors associated with longer survival.
Authors: Jan B Kuhlmann; Wulf Euringer; Hans C Spangenberg; Matthias Breidert; Hubert E Blum; Jan Harder; Richard Fischer Journal: Eur J Gastroenterol Hepatol Date: 2012-04 Impact factor: 2.566
Authors: Song Liu; Guangji Yu; Qingdong Wang; Long Li; Ying Liu; Ke Du; Fei Zhang; Bangli Zhao; Guangsheng Zhao Journal: Am J Transl Res Date: 2021-12-15 Impact factor: 4.060
Authors: Guido Poggi; Pietro Quaretti; Claudio Minoia; Giovanni Bernardo; Mario Regazzi Bonora; Raffaella Gaggeri; Anna Ronchi; Cesare Massa Saluzzo; Andrea Azzaretti; Giuseppe Rodolico; Michela Montagna; Alessio Amatu; Cristina Teragni; Ilaria Palumbo; Elena Traverso; Stefano Tonini; Laura Villani; Mario Scelsi; Paola Baiardi; Maria Grazia Felisi; Federico Sottotetti; Barbara Tagliaferri; Alberto Riccardi Journal: Anticancer Res Date: 2008 Nov-Dec Impact factor: 2.480